Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adaptation Disorders

Inclusion Criteria:

1. Men and women aged 18 to 70 years;

2. Availability of written consent to participate in the study in accordance withcurrent legislation;

3. Patients with anxiety and established diagnoses based on ICD-10 criteria:neurasthenia (F48.0) or adaptation reaction disorder (F43.2);

4. Anxiety severity on the HARS scale of 18-24 points;

5. Assessment of the severity of suicidal thoughts using the Columbia scale <3 points;

6. Severity of asthenia on the Multidimensional Fatigue Inventory Scale (MFI-20)greater than 50 points;

7. Total score on the Hamilton Depression Rating Scale (HAMD-17) < 6;

8. Score on the CGI-s scale of at least 4 points;

9. Negative pregnancy test for women with preserved reproductive potential;

10. Agreement to use effective contraceptive methods throughout the study and for 30days after its completion (for women with preserved reproductive potential and men);

11. Ability to understand the requirements placed on study participants, provide writtenconsent to participate in the study (including for the use and transfer ofinformation regarding the patients' health status relevant to the study), and complywith the procedures outlined in the study protocol.

Non-inclusion Criteria:

1. Known intolerance to the active and/or excipient substances contained in the studydrugs;

2. Known lactase deficiency, lactose intolerance, glucose-galactose malabsorption, orgalactose intolerance;

3. Patients requiring prohibited concomitant therapy within this study (MAO inhibitors,antidepressants, neuroleptics, anxiolytics and sedatives (including herbal),hypnotics when used on a regular basis), or who have taken these medications withinthe last month;

4. Established or suspected alcohol/narcotic substance use at the time of screening orrandomization, and/or a history of alcohol, narcotic, or drug dependence;

5. Presence of oncological diseases, including in history (except for cured tumors withstable remission for more than 5 years);

6. Presence of tuberculosis, including in history;

7. Presence of HIV, chronic viral hepatitis B/C, syphilis (including in history), or apositive test for HIV, hepatitis B/C, or syphilis during screening;

8. Patients with a diagnosis of other anxiety disorders (F41) established based onICD-10 criteria;

9. Schizophrenia, schizoaffective disorders, affective disorders, and panic disorders;

10. Acute psychosis (endogenous-processual, organic, or somatogenic), including inhistory;

11. Organic lesions of the central nervous system of traumatic and alcoholic origin;

12. Post-encephalitic syndrome;

13. Brain tumors, including in history;

14. Degenerative diseases of the central nervous system (CNS), particularly multiplesclerosis;

15. Depressions, including in history;

16. Suicide attempts in history;

17. Generalized anxiety disorder, including in history;

18. Epilepsy, seizures, including in history;

19. Decompensated diabetes mellitus;

20. Established diagnosis of chronic kidney disease stage 3A and above, or estimatedglomerular filtration rate (eGFR) calculated by the Cockcroft-Gault formula ≤ 59ml/min/1.73 m²;

21. Established diagnosis of liver failure of any severity, or elevated levels of ALT,AST or total bilirubin >3 times the upper limit of normal according to laboratorystandards;

22. Conditions following extensive surgical interventions if less than six months havepassed since the procedure;

23. Chronic heart failure III-IV functional class according to the New York HeartAssociation (NYHA) classification;

24. Severe, decompensated, or unstable diseases (any diseases or conditions thatthreaten the patient's life or worsen the patient's prognosis and make it impossibleto conduct clinical research on the patient);

25. Pregnant women, breastfeeding women, or those planning pregnancy during the studyand for 30 days after participation ends;

26. Refusal by the patient to use permitted methods of contraception or to completelyabstain from sexual contact throughout the entire period of participation in thestudy starting from Visit 0 and for 30 days after completion of participation;

27. Current participation or planned participation by the patient in psychological orpsychotherapeutic activities aimed at treating anxiety disorder during the clinicaltrial period;

28. Participation in any other clinical trial within 90 days prior to the start of thescreening period;

29. Lack of willingness to cooperate from the patient;

30. Other reasons that, in the investigator's opinion, prevent the patient fromparticipating in the study or pose an unjustified risk to the patient.

Exclusion Criteria:

1. The patient's desire to withdraw from the study (withdrawal of informed consent);

2. Each patient has the right to discontinue participation in the study at any timewithout explanation. Withdrawal from the study will not affect the medical careprovided to the patient in the future.

3. The investigator's decision that the patient needs to be excluded in the bestinterest of the patient;

4. The patient refuses to cooperate with the investigator or is non-compliant;

5. Emergence of reasons/situations during the study that threaten the patient's safety (e.g., hypersensitivity reactions, serious adverse events, etc.);

6. Inclusion of a patient in the study that does not meet the inclusion/exclusioncriteria, including cases of deviation from normal values in laboratory test resultsobtained at Visit 0;

7. Significant violation of the treatment regimen. A significant violation is considered:

8. Missing doses of the study drugs for 2 full consecutive days or more, or

9. Taking a total number of tablets < 80% or > 120% of the full course (the fullcourse for Ranquilon is 168 tablets, and for Afobazole, it is 84 tablets).

10. Positive pregnancy test;

11. Confirmed diagnosis of COVID-19;

12. Emergence of other reasons during the study that prevent its conduct according tothe protocol;

13. Patient death;

14. Termination of the study by the Sponsor;

15. Termination of the study by the Investigator;

16. Termination of the study by regulatory authorities.